British Vaccine Manufacturers: Industry Guide (2026)

The UK is the third-largest vaccine exporter in the world. In the last measured peak year, British vaccine manufacturers shipped over £3.2 billion worth of product, more than any other G7 country. That position was built on a handful of large-scale manufacturing sites, deep adjuvant and fill-finish expertise, and a biomedical research pipeline that still generates globally relevant innovations.

But the structure of the industry is changing fast. New modalities, new sites, new ownership, and a parliamentary debate about sovereign manufacturing capacity have reshuffled who matters, what they need, and how deals get done.

The core manufacturing sites

Seqirus in Liverpool is the biggest vaccine manufacturing facility in the UK and one of the largest influenza production sites in Europe. The site produces over 50 million doses of seasonal flu vaccine annually for domestic supply and global export. CSL, Seqirus’s parent company, has invested over $70 million in the Liverpool site in recent years to build integrated end-to-end manufacturing capability.

In 2024, UKHSA signed an advance purchase agreement with CSL Seqirus to be on standby to manufacture over 100 million strain-matched pandemic flu vaccines entirely within the UK if the World Health Organization declares a pandemic. It was the first deal of its kind to specify entirely UK-based production. The facility uses a scalable platform capable of delivering up to 200 million doses in the first manufacturing round after a pandemic declaration.

Professor Dame Jenny Harries, UKHSA Chief Executive, stated at the time: “Manufacturing these potentially life-saving vaccines inside the UK gives us speedier and more secure access.”

GSK’s UK network covers multiple sites with distinct roles. The Ware site in Hertfordshire handles biologics development and manufacturing, while Barnard Castle in County Durham has been earmarked for new aseptic sterile capacity. GSK announced £275 million in new UK manufacturing investment, with £92 million going to Barnard Castle for an aseptic facility supporting existing and new biopharmaceutical assets. GSK’s UK-developed adjuvant systems, including AS01 used in Shingrix and several malaria vaccine programmes, are among the most widely licensed vaccine adjuvant technologies in the world.

Valneva in Livingston, Scotland manufactures specialized travel vaccines and recently earned UK marketing authorization for the world’s first chikungunya vaccine, IXCHIQ, manufactured entirely at the Livingston site. In February 2025, the MHRA granted authorization for IXCHIQ, making it the first and only licensed chikungunya vaccine globally. The site also supports late-stage development of a Lyme disease vaccine candidate partnered with Pfizer.

Moderna’s Oxfordshire facility opened in 2024 and is now authorized to produce mRNA respiratory vaccines for the UK market. The site at the Harwell Science and Innovation Campus has capacity to produce up to 100 million mRNA vaccine doses per year, scaling to 250 million during a declared pandemic. This is the UK’s first purpose-built commercial mRNA manufacturing facility, and it underpins a 10-year strategic partnership between Moderna and the UK government.

Catalent at Harwell took over the former Vaccine Manufacturing and Innovation Centre (VMIC) built with £215 million in government funding. The facility was purpose-built for mRNA, protein, and viral vector modalities, and CDMO Catalent acquired it to serve external biotech and pharma clients needing advanced vaccine manufacturing services.

The sovereign capacity debate

Not everything is stable. The House of Lords Science and Technology Committee raised formal concerns in December 2024 about the UK’s capacity to manufacture vaccines in a future pandemic. The committee warned that the UK risks being overly reliant on a single technology platform (mRNA) through its Moderna partnership, and called for a diversified portfolio of manufacturing capabilities covering multiple modalities.

The concerns are specific. AstraZeneca scrapped plans to expand a Liverpool vaccine manufacturing site in early 2025, citing reduced UK government funding. The Valneva Livingston facility faces uncertainty after CSL Seqirus underwent corporate restructuring affecting adjacent operations. The committee recommended a dedicated “peacetime vaccines taskforce” to sustain domestic manufacturing capability between emergencies.

In response, the UK government allocated around £1 billion for health protection as part of a 2026 Pandemic Preparedness Strategy, with vaccine manufacturing capability a stated priority.

This tension between strong research output and manufacturing continuity is the defining theme for the sector right now. UK vaccine manufacturers operate in an environment where funding decisions, regulatory shifts, and geopolitical factors move fast.

What gets made where

The UK vaccine manufacturing base covers several distinct production categories:

Inactivated and adjuvanted influenza vaccines

Seqirus in Liverpool owns this space at scale. The site handles cell-based production, egg-based production, and adjuvanted seasonal flu formats including MF59-adjuvanted Fluad for older adults.

Viral vector vaccines

Oxford Biomedica’s Oxbox facility near Oxford produced the bulk drug substance for the Oxford-AstraZeneca COVID-19 vaccine. The site has GMP-certified capacity for large-scale adeno-associated virus and lentiviral vector production. Fill-finish operations for viral vector vaccines have been handled by Wockhardt at sites in North Wales and the Midlands.

mRNA vaccines

Moderna’s Harwell facility and the Catalent VMIC both target this modality. Neither existed at commercial scale in the UK before 2022. Both are now operational.

Travel and specialty vaccines

Valneva Livingston covers chikungunya, Japanese encephalitis, and tick-borne encephalitis formats, plus Lyme disease in late-stage development. This niche, but globally significant, market serves travel clinics, military procurement, and endemic disease programmes.

Adjuvant systems

GSK’s adjuvant development operations span multiple UK sites. Adjuvants are not vaccines themselves, but without proprietary adjuvant systems like AS01, AS03, and AS04, many modern vaccines would not generate sufficient immune response. UK adjuvant expertise differentiates domestic manufacturers from lower-cost competitors who cannot replicate proprietary adjuvant formulations.

The sales channels losing ground

British vaccine manufacturers sell into procurement systems that are slow, relationship-dependent, and increasingly expensive to maintain. The conventional channels are under pressure.

Trade fairs: Vaccine World Congress and CPhI Worldwide

These are the primary commercial networking events for vaccine manufacturers and their buyers. The World Vaccine Congress Europe attracts over 550 speakers and 300+ exhibitors annually. A stand plus travel and personnel runs £15,000 to £50,000 per event. You meet procurement contacts, partnership managers, and distributor reps. You rarely get direct access to the procurement directors, supply chain leads, and regulatory affairs managers who actually drive buying decisions at large buyers like national immunization programmes, multilateral procurement bodies, or large hospital systems. Cost per qualified lead: £300 to £900+.

Government tender networks and multilateral channels

The UK’s vaccine exporters have historically relied on relationships with bodies like UNICEF Supply Division, GAVI the Vaccine Alliance, and PAHO for developing-market volumes. Those relationships are institutional, slow to build, and hard to replicate. They also do not help with commercial sales into EU, US, or Asia-Pacific hospital and clinic networks.

Field sales teams and KOL networks

A pharmaceutical commercial director with vaccine expertise costs £70,000 to £100,000 annually in salary, before bonuses, benefits, and travel. To cover five export markets with genuine sector depth, you need five people. The total loaded cost per rep easily exceeds £130,000 per year. Cost per qualified lead: £500 to £1,200+. And KOL-based selling, while effective for scientific credibility, does not scale. Each relationship takes months to develop and covers a narrow area.

Cold calling across multiple markets

Reaching a procurement committee at a national health authority or large hospital group requires getting to multiple contacts: procurement, clinical pharmacist, supply chain, regulatory affairs, quality. That means 20 to 30 call attempts per account, across different time zones, in the buyer’s native language, with technical depth. For a single rep managing 60 accounts across three continents, the math does not work.

The structural problem is always the same: these channels reach one stakeholder at a time in an industry where supplier qualification involves five to ten people and takes six to eighteen months.

Where AI-powered outbound fits

AI-powered outbound is not a substitute for regulatory competence or manufacturing quality. It is a prospecting tool that does what human-scale outreach cannot: reach all relevant decision-makers across hundreds of target accounts simultaneously, with messaging personalized to their role.

For a vaccine CDMO with fill-finish capacity, the outreach to a large biotech buyer looks different depending on who receives it. The VP of Supply Chain wants to know about batch sizes, lead times, and GMP certification status. The Head of Regulatory Affairs wants to know about your CMC documentation track record and MHRA/EMA submission support. The CMO wants to know about your experience with their specific modality.

An AI outbound system sends each of them the right version. And it monitors signals: a biotech announcing positive Phase II results for a vaccine candidate, a national immunization programme announcing a new tender, a distributor reporting capacity constraints. When those signals appear, the outreach goes out at the moment a buyer is most likely to respond.

See how papaverAI builds this for vaccine and pharma manufacturers.

Cost per qualified lead with AI-powered outbound: $150 to $300, dropping further as the system learns which messaging, timing, and targeting performs. That is roughly one-fifth the cost of a trade fair lead. The more the system runs, the better it gets. A trade fair costs the same every year. AI outbound compounds.

For smaller UK vaccine manufacturers and CDMOs

The big names like GSK and Seqirus sell through institutional channels most smaller manufacturers cannot access directly. But the UK’s broader vaccine supply chain, covering adjuvant manufacturers, glass vial producers, cold chain logistics, viral vector CDMOs, and analytical testing labs, faces the same commercial problem at smaller scale.

A UK specialist in biologics fill-finish looking to expand into EU clinical-stage biotech clients cannot sustain a field sales operation covering Germany, France, Switzerland, and the Netherlands. The headcount and travel budget required exceed what a mid-sized CDMO can justify without guaranteed pipeline. AI outbound solves this by enabling one commercial director to effectively prospect 400 accounts across five countries simultaneously, qualifying leads before a single call happens.

The UK life sciences sector is projected to need 70,000 new jobs by 2035, according to the BioIndustry Association. The commercial infrastructure needs to keep pace with that growth or companies will build capacity they cannot fill.

Frequently asked questions

Who are the main vaccine manufacturers operating in the UK?

The main commercial-scale vaccine manufacturers in the UK include CSL Seqirus (Liverpool, flu vaccines), GSK (Ware and Barnard Castle, biologics and adjuvant systems), Valneva (Livingston, Scotland, travel vaccines), Moderna (Harwell, Oxfordshire, mRNA vaccines), and Catalent at the former VMIC site (Harwell, multi-modality CDMO). Oxford Biomedica handles large-scale viral vector manufacturing near Oxford.

What vaccine modalities does the UK produce at commercial scale?

The UK currently produces inactivated and adjuvanted influenza vaccines at the largest scale. Viral vector manufacturing was demonstrated at scale during the COVID-19 response and continues through Oxford Biomedica. mRNA is now commercially established through Moderna’s Harwell facility. Fill-finish capacity exists at several sites including Wockhardt. Adjuvant systems development is concentrated at GSK.

How significant are UK vaccine exports?

UK vaccine exports reached £3.2 billion in the last peak year, making the UK the third-largest vaccine exporter globally and the largest among G7 countries. The broader pharmaceutical export figure was £24.6 billion in 2024, with vaccines representing the most internationally recognized part of the sector. The US accounts for the majority of UK vaccine export value.

What are the main challenges for British vaccine manufacturers selling internationally?

The main commercial challenge is reaching procurement decision-makers at foreign government health agencies, hospital networks, and pharmaceutical companies before competitors do. UK manufacturers traditionally rely on trade fairs, distributor networks, and KOL relationships, all of which are expensive per qualified lead and do not scale across multiple export markets simultaneously. Navigating dual MHRA and EMA regulatory requirements adds complexity for EU-facing sales.

How is the UK government supporting vaccine manufacturing capacity?

The government allocated approximately £1 billion for health protection under its 2026 Pandemic Preparedness Strategy. Prior investments include £215 million for the VMIC at Harwell (now operated by Catalent), the UKHSA advance purchase agreement with Seqirus for pandemic flu manufacturing, and the Moderna strategic partnership for domestic mRNA production. The House of Lords Science and Technology Committee has called for a diversified approach beyond mRNA reliance.

---

UK vaccine manufacturers building commercial pipeline in international markets can explore how papaverAI’s growth engine approaches B2B outbound for life sciences manufacturers. For context on broader UK pharma commercial challenges, see our post on UK pharma and biotech exporters and the full UK manufacturing overview.